The Anatomic and Functional Outcomes of Ozurdex-Aided Vitrectomy in Proliferative Diabetic Retinopathy

• DOI: 10.2147/dmso.s445607
• Publication Date: 2024-03-07T15:20:05Z
• Authors: Manqiao Wang; Rong Luan; Boshi Liu; Yi Gong; Jinzhi Zhao; Xiteng Chen; Qianhui Yang; Jingjie Liu; Juping Liu; Yan Shao; Xiaorong Li
• Keywords: Plexus; Diabetic macular edema

Purpose: To investigate the 3-months outcomes of patients who underwent intraoperative intravitreal injection Ozurdex for proliferative diabetic retinopathy (PDR).Methods: This is a prospective randomized controlled clinical trial (ChiCTR2100043399).Seventy-one with PDR had indications surgery without history within 3 months preoperatively were enrolled.Patients randomly divided into three groups based on medicine injected intraoperatively: Ozurdex, Conbercept, and Control group.The primary outcome best-corrected visual acuity (BCVA) postoperatively.The secondary include intraocular pressure (IOP), mean sensitivity, central retinal thickness vessels perfusion. Results:The BCVA sensitivity improved in (F = 130.8, P < 0.0001; F 34.18,P 0.0001), but there was no statistical difference among 0.858, 0.552; 0.964, 0.452).The IOP significant differences postoperatively 0.881, 0.533).Compared other two groups, (CRT) outer layer (ORL) decreased significantly group 3.037, 0.008; 2.626, 0.018), especially macular edema (DME) 2.761, 0.0164; 2.572, 0.0240).In region, superficial vascular plexus (SVP), intermediate capillary (ICP) deep (DCP) perfusion not shown at all compared 1 day (P > 0.05). Conclusion:Compared anatomical DR patients.Ozurdex may help to improve change microvascular improvement.Clinical Trial Registration: registered Chinese Clinical Registry (http://www.chictr.org.cn,registration number ChiCTR2100043399).